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Stakeholders in Cutaneous 
Investigation: Patients and Patient 
Advocates Are Essential
Paul R. Bergstresser1, John T. Grupenhoff2 and Vicki Kalabokes3
A diverse array of stakeholders supports biomedical investigation, the major 
goal of which is to improve human health. For patients with dermatological 
disease, the Coalition of Skin Diseases (CSD) has for more than two decades 
provided a base from which public advocacy, education, fund-raising, and 
communication have flourished. Their efforts, combined with that of investi-
gators and national funding agencies, have advanced scientific enterprise and, 
ultimately, human health.
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Effective biomedical investigation does 
not begin and end with the investigators 
who work in laboratories; rather, suc-
cessful investigation requires a diverse 
array of “stakeholders.” These may 
include nonprofit funding agencies, for-
profit industries, research institutions, 
advocacy organizations, patients, and 
patient advocates. Each stakeholder 
has considerable interest in the discov-
eries and therapies that emerge from 
investigation, and each may be consid-
ered essential, but not sufficient. The 
authors of this contribution to the 75th 
Anniversary Supplement to the Journal 
of Investigative Dermatology have sup-
ported the interplay among these inter-
ests from four perspectives: Bergstresser 
as editor-in-chief of JID, a medium 
of scientific communication, and as 
secretary–treasurer of the Society for 
Investigative Dermatology (SID), a 
nonprofit professional organization; 
Grupenhoff as a legislative consultant, 
based in Washington, DC, for nonprofit 
advocacy organizations, including the 
SID; and Kalabokes as president and 
chief executive officer of a success-
ful national patient-advocacy organi-
zation, the National Alopecia Areata 
Foundation (NAAF) and also past chair 
of the Coalition of Skin Diseases (CSD). 
We have served as advocates in support 
of research, effective therapies, access 
to information for patients with skin dis-
ease, and money to conduct research. 
We write to describe the essential roles 
of these stakeholders, with emphasis on 
patient advocacy.
To set the background, however, it is 
important to recognize that biomedical 
research is most often directed toward 
human health. Support for this asser-
tion may be seen in published goals of 
the three largest funding agencies in the 
United States: the National Institutes of 
Health (NIH), the Bill & Melinda Gates 
Foundation (Gates Foundation), and 
the Howard Hughes Medical Institute 
(HHMI). A review of their missions and 
guiding principles gives insight into the 
degree to which their monies and influ-
ence are directed toward health:
NIH: “NIH is the steward of medical 
and behavioral research for the Nation. 
Its mission is science in pursuit of fun-
damental knowledge about the nature 
and behavior of living systems and the 
application of that knowledge to extend 
healthy life and reduce the burdens of 
illness and disability” (http://www.nih.
gov/about/mission.htm, 21 July 2011).
Gates Foundation: “Guiding 
Principle #3: Science and technology 
have great potential to improve lives 
around the world” (http://www.gates-
foundation.org/about/Pages/guiding-
principles.aspx, 21 July 2011).
HHMI: Its “flagship program in bio-
medical research rests on the convic-
tion that scientists of exceptional talent, 
commitment, and imagination will make 
fundamental biological discoveries for 
the betterment of human health if they 
receive the resources, time, and freedom 
to pursue challenging questions” (http://
www.hhmi.org/about, 21 July 2011).
To be certain, the efforts of the 
stakeholders we describe here would 
be in vain without the primary con-
tributions of researchers, who make 
scientific discoveries and ultimately 
help to forge novel therapies, and of 
reviewers and editors, who vet and 
help disseminate new information 
important to human health. Their role 
in the scientific enterprise is evident 
but not considered here in detail.
Similarly important are the contri-
butions of information resources, the 
majority of which are supported by the 
US federal government but are available 
to investigators worldwide, for example:
•  National Library of Medicine 
(http://www.nlm.nih.gov)
•  National Center for Biotechnology 
Information (http://www.ncbi.
nlm.nih.gov)
•  PubMed (http://www.ncbi.nlm.
nih.gov/pubmed)
•  Online Mendelian Inheritance in 
Man (http://www.ncbi.nlm.nih.
gov/omim)
Patients and patient advocacy
Sixteen patient-advocacy organiza-
tions having interest in skin disease 
now combine their efforts and 
resources in the CSD, a collective 
organization (http://www.coalition-
ofskindiseases.org). The CSD was 
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formed in the mid-1980s to promote 
skin disease research and to share in 
networking in ways that improve the 
success of each member organiza-
tion. The coalition was the idea of 
Peyton Weary, at that time chairman 
of the Department of Dermatology 
at the University of Virginia (and 
subsequently an honorary member 
of the SID). He realized, after serv-
ing for many years advocating der-
matological research on Capitol Hill 
in Washington, DC, that the voices 
of patients were needed when deal-
ing with Congress. One of the CSD’s 
first successes was the help they pro-
vided in establishing the first NIH 
institute with “skin” in its name, the 
National Institute of Arthritis and 
Musculoskeletal and Skin Diseases 
(NIAMS). The inclusion of “skin” was 
a major achievement in promoting 
research awareness for skin diseases. 
The CSD was also a major player in 
the initiation of NIAMS Skin Disease 
Research Core Center Grants, which 
were funded less than a decade later. 
These grants, now six in number, have 
helped to make skin disease research 
increasingly visible, not only to a 
series of academic medical centers 
but also to the research establish-
ment nationally. It has been a major 
achievement (Jones and Kalabokes, 
2010).
In terms of the “political process,” 
coalition groups and the CSD itself 
have provided oral and written testi-
mony on numerous occasions before 
the US Senate and House appropria-
tions subcommittees on labor, health 
and human services, education, and 
related agencies, promoting medical 
research in general as well as skin dis-
ease research in particular. The coali-
tion and individual groups have also 
been successful in securing report lan-
guage in appropriations bills that have 
been passed by the US Congress.
Member organizations of the CSD, 
in addition to pooling their efforts to 
improve funding for research in gen-
eral, have at the same time recruited 
resources to meet their own specific 
interests. This has included direct 
funding of research, patient and 
family counseling, electronic and 
print information resources, sup-
port networks, patient conferenc-
es, research workshops, and social 
media. We applaud their efforts.
Useful information about the 
mechanisms by which advocacy 
organizations have helped clinical 
scientists work with patients may be 
found in the article by Kalabokes (2011). 
Several examples of successful activities 
of the NAAF illustrate the interests that 
typify advocacy organizations.
the “jump start”
One problem commonly encountered 
by advocacy groups is that the num-
ber of patients affected by the disease 
of interest is insufficient to gain rec-
ognition or significant funding from 
national agencies. In addition, new 
advocacy organizations have little 
experience in identifying sources 
of administrative advice or fund-
ing. Recognizing these limitations, 
in 1985 the NAAF, working with an 
advisory council, initiated a program 
of small seed grants. Based on the 
subsequent success of the research 
funded by these grants, investigators 
were able to leverage that funding 
into successful applications for NIH 
support.
Gleaning information
One of the benefits of attending sev-
eral of the early “advocacy” days on 
Capitol Hill (see below) was learn-
ing about the “goals” of the NIAMS 
(see above). Inspired by what mem-
bers of the organization learned, the 
NAAF was successful in cosponsor-
ing a series of research workshops 
about hair. The goal was to facili-
tate the identification of appropriate 
directions for its research agenda. 
Ultimately, this was successful. For 
example, seed money that the NAAF 
had invested in the C3H HeJ mouse 
model led to new NIH-supported 
studies of alopecia areata genetics 
and hair follicle stem cell biology. 
Taken together, these initial efforts led 
to substantial NIH funding and more 
than 60 published articles in journals, 
including Nature and JID.
naaF as a model for other organizations
The NAAF has served as a “mentor” 
for several other CSD organizations 
as well as for nondermatological 
organizations, including advocacy for 
breast cancer and Duchenne muscular 
dystrophy. The NAAF’s research pro-
gram may be seen as a model for 
patient advocacy organizations.
Sharing information
One of the advantages of the CSD is 
that information about successful 
ventures has been shared among its 
members. It is important to note that 
the organizations that comprise the 
CSD do not ordinarily compete with 
one another because the donors and 
supporters of their activities tend to 
have interests limited to unique dis-
eases. Because of this, the NAAF and 
other CSD members have willingly 
shared resources, including applica-
tion forms, peer review processes, 
confidentiality agreements, and con-
flict of interest statements, as well 
as organizational procedures. In 
fact, all CSD members have tended 
to share their best practices in virtu-
ally all aspects of their missions. The 
groups are relatively ecumenical and 
act to keep all member organizations 
strong and effective (http://www. 
coalitionofskindiseases.org/).
For whom do the funding agencies, 
professional societies, and investigators 
and advocacy groups work?
We have previously asserted that 
these efforts of stakeholders are “all 
about patients” (Bergstresser, 2010). 
We emphasized that scholarly jour-
nals such as JID commonly lack 
descriptions of what it is to be “ill at 
ease” about one’s health, that is, to 
have a disease. In fact, many of the 
investigators who contribute to JID 
and other journals do know quite well 
what it is like to have diseases such 
as pemphigus, squamous cell carci-
noma, or psoriasis because they con-
duct research with their own patients. 
On the other hand, they rarely have 
an opportunity to write about the 
impact of such diseases on the lives 
of their patients. Ordinarily, it is not 
the responsibility of the journals 
that publish original research to do 
this. Rather, we assert that this is the 
responsibility of patients and patient 
advocates, although this is done most 
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effectively when advocates collabo-
rate with the relevant investigators.
An example of the importance of 
patient advocates in national politics 
may be illustrated through a personal 
experience. For a number of years, 
the CSD, in association with mem-
bers of the SID and the American 
Academy of Dermatology, has par-
ticipated in an advocacy meeting in 
Washington, DC. During this time, 
representatives of these organizations 
would visit congressional and senate 
offices of legislators on Capitol Hill. 
Meeting with congressional/senate 
aides, and sometimes with elected 
officials, they describe patients’ expe-
riences as they advocate for research 
and patient-care goals of the NIH and 
other federal agencies. As a long-time 
participant, Bergstresser frequently 
observed that the aides, better known 
as “staffers,” in congressional offices 
were primarily interested in the CSD 
advocates and in voters from their 
own districts whereas interest in the 
investigators was modest at best. 
We learned quickly that medical 
investigators and practicing physi-
cians should enter the room last and 
speak only when spoken to. In sum, it 
was all about voters, advocates, and 
patients, not the investigators.
In a special issue of JID Symposium 
Proceedings, the “burden of skin dis-
ease” was addressed in considerable 
depth (March 2004). Although we 
will not repeat what was written, a 
list of some of the articles published 
in that issue provides insight into the 
importance of the proceedings and 
the importance of patients and their 
points of view:
•  “Emotions of the Disease” 
(Williams, 2004)
•  “Patient Advocacy and Patient 
Perspective of Skin Disease” 
(Heuring, 2004)
•  “Defining the Burden of Skin 
Disease in the United States—A 
Historical Perspective” (Johnson, 
2004)
•  “Self-Reported Skin Morbidity 
among Adults: Associations 
with Quality of Life and General 
Health in a Norwegian Survey” 
(Dalgard et al., 2004)
•  “The Burden of Psoriasis Is Not 
Determined by Disease Severity 
Only” (Heydendael et al., 2004)
•  “Psoriasis Is Common, Carries a 
Substantial Burden Even When 
Not Extensive, and Is Associated 
with Widespread Treatment 
Dissatisfaction” (Stern et al., 2004)
To begin to address this gap, we des-
ignated 2010 “The Year of the Patient” 
and dedicated 12 issues of JID to 
patients. Our intent was to describe to 
the scientific world at large the burden 
that patients with skin disease bear. 
One of the features of the 2010 issues 
arose from an activity headed by staff 
members of the SID and members of 
the CSD. They established an art and 
poetry exhibition that was displayed 
at each SID Annual Meeting for four 
years. The works on display provided 
extraordinary insight into the impact 
of disease on the lives of patients. In 
2010, work from these artists was fea-
tured on the cover of each issue of the 
Journal. In addition, editorial space was 
devoted to poetic descriptions of dis-
ease, written by patients. We assured 
our audience that the intensity and cre-
ativity displayed in these contributions 
would fortify their creative spirits as 
they pursued their research.
In sum, we assert that patients and 
patient advocates represent an impor-
tant—perhaps the most important—con-
stituency in the biomedical enterprise.
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